Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer : A cost-effectiveness analysis

Current chemotherapy in platinum-resistant ovarian cancer patients has demonstrated minimal to no improvements in survival. Despite the lack of benefit, significant resources are utilized with such therapies. Therefore, the objective in the current study was to assess the cost-effectiveness of salva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2006-08, Vol.107 (3), p.536-543
Hauptverfasser:	ROCCONI, Rodney P, CASE, Ashley S, STRAUGHN, J. Michael, ESTES, Jacob M, PARTRIDGE, Edward E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - economics Biological and medical sciences Cisplatin - therapeutic use Cost-Benefit Analysis Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Doxorubicin - therapeutic use Drug Resistance, Neoplasm Epithelial Cells - pathology Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Models, Economic Neoplasm Recurrence, Local Ovarian Neoplasms - drug therapy Ovarian Neoplasms - economics Ovarian Neoplasms - epidemiology Platinum - pharmacology Platinum - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!